Naslov
Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3 month follow-up

Autori
Medved, Vesna ; Rojnić Kuzman, Martina ; Jovanović, Nikolina ; Grubišin, Jasmina ; Kuzman, Tomislav

Izvornik
Journal of psychopharmacology (0269-8811) 23 (2009), 8; 915-922

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
diabetes ; female ; metabolic syndrome ; olanzapine ; risperidone ; schizophrenia

Sažetak
The objective of this study was to determine the occurence of metabolic abnormalities among previously unmedicated female patients with Diagnostic and Statistical Manual of Mental Disorders ; fourth Edition schizophrenia spectrum disorders and theit associations with olanzapine and risperidone treatment. We analysed 94 female patients who were treated with olanzapine or risperidone in the period of 3 months. Analysed variables included fasting glucose, total cholesterol, low-density lipoproteine (LDL), high-density lipoproteine (HDL)and triglicerides in blood, blood pressure (BP), waist and hip circumference and body mass indey (BMI). At baseline, 14 patients (15%) fulfilled criteria for metabolic syndrome. After 3 months of treatment, 25 patients (27%) fulfilled criteris for metabolic syndrome, and their baseline BMI was the only predictor for its development. Treatment with both antipsychotics was associated with significant increase in waist circumference. Positive family history of diabetes mellitus contributed to a significant greater increase in abdominal obesity, significant higher baseline levels and a borderline significant increase in fasting glucose among olanzapine-treatde patients. Olanzapine admission was associated with significant increase in LDL and risperidone with a significant increase in triglycerides. Metabolic abnormalities seem to be more prevalent in unmedicated female patients with schizopghrenia spectrum disorders than expected based on results in general population (adjusted for age and sex). Olanzapine treatment might induce significant alterations in metabolic profiles, especially among patients with positive family history of diabetes, mostly by inducing abdominal obasity. The association of risperidone application and increase in triglyceride level still need to be determinated.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA